Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty.
The use of abciximab after full-dose failed thrombolytics within 15 hours of acute myocardial infarction significantly increases the risk of major bleeding complications.
Sundlof
D W
DW
Division of Cardiovascular Medicine, Albert Einstein Medical Center, Philadelphia, Pennsylvania 19141, USA.
Rerkpattanapitat
P
P
Wongpraparut
N
N
Pathi
P
P
Kotler
M N
MN
Jacobs
L E
LE
Ledley
G S
GS
Yazdanfar
S
S
D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D005260:Female; D006470:Hemorrhage / Q000453:epidemiology* / Q000209:etiology; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects*; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy / Q000628:therapy; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D012189:Retrospective Studies; D015912:Thrombolytic Therapy
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab